Cognitive Function, Motor Activity, Obesity
Conditions
Brief summary
The BrainFit Study aims to examine acute effects of High Intensity Interval- vs Resistance or Combined program has benefits on Cognitive Function as well as on secretion and regulation of neurotrophic factors or neurotrophins in a cohort of sedentary, overweight adults (aged 18-30 years) from Bogota, Colombia.
Interventions
BEHAVIORALExperimental: High Intensity Interval
Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 500 kcal
BEHAVIORALResistance training
Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 500 kcal
Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached
OTHERNon-exercise
This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
Sponsors
Universidad del Rosario
Universidad Nacional de Colombia
Universidad Santo Tomas
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 30 Years
Healthy volunteers
Yes
Inclusion criteria
* Written informed consent. * Interested in improving health and fitness. * Central obesity: waist circumference ≥90cm * Body mass index ≥ 26 kg/m(2)
Exclusion criteria
* Systemic infections. * Weight loss or gain of \>10% of body weight in the past 6 months for any reason. * Currently taking medication that suppresses or stimulates appetite. * Uncontrolled hypertension: systolic blood pressure 160 mm Hg or diastolic blood pressure 95 mm Hg on treatment. * Gastrointestinal disease, including self-reported chronic hepatitis or cirrhosis, any episode of alcoholic hepatitis or alcoholic pancreatitis within past year, inflammatory bowel disease requiring treatment in the past year, recent or significant abdominal surgery (e.g., gastrectomy). * Asthma. * Diagnosed diabetes (type 1 or 2), fasting impaired glucose tolerance (blood glucose 118 mg/dL), or use of any anti-diabetic medications. * Currently taking antidepressant, steroid, or thyroid medication, unless dosage is stable (no change for 6 months). * Any active use of illegal or illicit drugs. * Current exerciser (\>30 min organized exercise per week). * Indication of unsuitability of current health for exercise protocol (PARQ).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline in Brain-derived neurotrophic factor | Baseline and 60 minutes immediately after the interventions ends | Measurement of serum Brain-derived neurotropic factor true blood samples. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline in Neurotrophin-3 | Baseline and 60 minutes immediately after the interventions ends | — |
| Change from Baseline in Neurotrophin-4 | Baseline and 60 minutes immediately after the interventions ends | — |
| Change from Baseline change in Cognitive Function | Baseline and 60 minutes immediately after the interventions ends | Cognitive Performance Test (BPT) computerized cognitive assessment battery developed by Lumos Labs, Inc. |
Countries
Colombia
Outcome results
None listed